$54.27
0.10% today
Nasdaq, Aug 18, 08:17 pm CET
ISIN
US87650L1035
Symbol
TARS

Tarsus Pharmaceuticals Inc Stock price

$54.21
+13.63 33.59% 1M
+3.99 7.95% 6M
-1.16 2.10% YTD
+27.25 101.08% 1Y
+35.82 194.78% 3Y
+38.21 238.81% 5Y
+38.21 238.81% 10Y
+38.21 238.81% 20Y
Nasdaq, Closing price Fri, Aug 15 2025
+0.07 0.13%
ISIN
US87650L1035
Symbol
TARS
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.0b
Net debt
positive
Cash
$407.9m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.8 | 5.6
EV/Sales
6.6 | 4.8
EV/FCF
negative
P/B
6.7
Financial Health
Equity Ratio
59.6%
Return on Equity
-51.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$295.5m | $407.9m
EBITDA
$-96.4m | $-62.4m
EBIT
$-98.0m | $-63.2m
Net Income
$-92.0m | -
Free Cash Flow
$-87.8m
Growth (TTM | estimate)
Revenue
254.5% | 123.0%
EBITDA
37.9% | 47.7%
EBIT
37.3% | 47.6%
Net Income
38.7% | -
Free Cash Flow
32.2%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
-32.6% | -15.3%
EBIT
-33.2%
Net
-31.1% | -
Free Cash Flow
-29.7%
More
EPS
$-2.2
FCF per Share
-
Short interest
19.9%
Employees
323
Rev per Employee
$570.0k
Show more

Is Tarsus Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Tarsus Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Tarsus Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Tarsus Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
296 296
254% 254%
100%
- Direct Costs 20 20
214% 214%
7%
276 276
258% 258%
93%
- Selling and Administrative Expenses 315 315
71% 71%
107%
- Research and Development Expense 59 59
18% 18%
20%
-96 -96
38% 38%
-33%
- Depreciation and Amortization 1.63 1.63
48% 48%
1%
EBIT (Operating Income) EBIT -98 -98
37% 37%
-33%
Net Profit -92 -92
39% 39%
-31%

In millions USD.

Don't miss a Thing! We will send you all news about Tarsus Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tarsus Pharmaceuticals Inc Stock News

Neutral
Seeking Alpha
11 days ago
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Aziz Mottiwala - Chief Commercial Officer Bobak R. Azamian - Co-Founder, President, CEO & Chairman David Nakasone - Head of Investor Relations Jeffrey S.
Neutral
GlobeNewsWire
12 days ago
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year
Neutral
GlobeNewsWire
19 days ago
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 2025 financial results and provide a corporate update.
More Tarsus Pharmaceuticals Inc News

Company Profile

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Head office United States
CEO Bobak Azamian
Employees 323
Founded 2017
Website www.tarsusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today